NCT01583842 - 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 9, 2013

Primary Completion Date

February 25, 2021

Study Completion Date

February 25, 2021

Conditions

Neuroblastoma

Interventions

DRUG

124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)

"124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration \& PET/CT scan 6 weeks later."

DRUG

124I-MIBG (carrier added)

"124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration \& PET/CT scan 6 weeks later."

PROCEDURE

Positron Emission Tomography (PET) /Computerized tomography (CT)

A PET scan measures important body functions, such as metabolism. CT imaging uses special x-ray equipment, and in some cases a contrast material, to produce multiple images of the inside of the body. Combined PET/CT scans combine the processes of both a PET and CT at the same time.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco